ReNeuron Group plc - AGM Trading Update
ReNeuron Group plc
AGM Trading Update
We continue to progress the clinical development of our human retinal progenitor cell ("hRPC") therapy candidate in the blindness-causing disease, retinitis pigmentosa ("RP"). A Phase 1/2a open-label clinical trial is ongoing to evaluate the safety, tolerability and preliminary efficacy of our hRPC stem cell therapy candidate in patients with advanced RP.
Dosing of the third cohort of three subjects in the Phase 2a element of the study is complete and dosing of the remaining cohort is underway. These later cohorts include patients with a greater baseline level of visual acuity than those patients earlier in the study, as we seek to assess preliminary efficacy in patient groups with differing levels of remaining vision.
We expect to report preliminary data next month from all treated Phase 2a subjects at the
Our CTX cell therapy candidate for stroke disability is currently being evaluated in the PISCES III clinical study, a randomised, placebo-controlled, Phase 2b clinical trial in 110 patients in the US. Due to the nature and complexity of the study, patient recruitment has been slower than anticipated and we are pursuing or evaluating a number of further initiatives to address this. These include potential amendments to the clinical trial protocol as well as various patient recruitment initiatives to better target eligible patients for the study.
As a result of the above, we anticipate that the time to PISCES III clinical trial read-out will be extended by approximately 3-6 months, in the first half of 2021.
Our exosome technology is being exploited as a novel vector for delivering third party biological drugs. In
Following the licence agreement signed with
We remain in discussions with other commercial third parties regarding potential collaboration and/or out-licensing deals across our programmes.
| || |
+44 (0)20 3819 8400
| || |
| || |
+44 (0) 20 7466 5000
+1 212 600 1902
+44 (0) 20 7710 7600
| || |
+44 (0) 20 7496 3000
This information is provided by RNS, the news service of the
Quick facts: ReNeuron Group PLC
Market Cap: £43.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE